-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Imago BioSciences (NASDAQ:IMGO) Shares Gap Down to $15.29
Imago BioSciences (NASDAQ:IMGO) Shares Gap Down to $15.29
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) gapped down before the market opened on Friday . The stock had previously closed at $15.29, but opened at $14.61. Imago BioSciences shares last traded at $15.26, with a volume of 105 shares trading hands.
Analyst Upgrades and Downgrades
Separately, HC Wainwright cut their price objective on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Stock Performance
The company's 50-day moving average is $16.20 and its 200 day moving average is $16.33. The company has a market capitalization of $507.79 million, a PE ratio of -8.46 and a beta of 2.48.
Insider Activity at Imago BioSciences
In related news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $19.41, for a total transaction of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at approximately $2,888,382.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 8,168 shares of company stock valued at $155,402. 14.90% of the stock is owned by insiders.Hedge Funds Weigh In On Imago BioSciences
Several hedge funds and other institutional investors have recently bought and sold shares of IMGO. Ensign Peak Advisors Inc bought a new position in Imago BioSciences during the 4th quarter valued at about $593,000. Citadel Advisors LLC lifted its stake in Imago BioSciences by 20.1% during the 4th quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after acquiring an additional 410,487 shares during the period. Woodline Partners LP lifted its stake in Imago BioSciences by 101.9% during the 4th quarter. Woodline Partners LP now owns 848,129 shares of the company's stock valued at $20,109,000 after acquiring an additional 428,127 shares during the period. Emerald Advisers LLC lifted its stake in Imago BioSciences by 7.0% during the 1st quarter. Emerald Advisers LLC now owns 616,368 shares of the company's stock valued at $11,877,000 after acquiring an additional 40,209 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in Imago BioSciences by 106.6% during the 1st quarter. New York State Common Retirement Fund now owns 13,391 shares of the company's stock valued at $258,000 after acquiring an additional 6,909 shares during the period. Institutional investors own 99.50% of the company's stock.
Imago BioSciences Company Profile
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Recommended Stories
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) gapped down before the market opened on Friday . The stock had previously closed at $15.29, but opened at $14.61. Imago BioSciences shares last traded at $15.26, with a volume of 105 shares trading hands.
週五開盤前,Imago BioSciences,Inc.(納斯達克代碼:IMGO-GET Rating)的股價大幅下跌。該股此前收盤報15.29美元,開盤報14.61美元。Imago BioSciences的股票最新報15.26美元,成交量為105股。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, HC Wainwright cut their price objective on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
另外,在8月16日(星期二)的一份研究報告中,HC Wainwright將Imago BioSciences的股票目標價從36.00美元下調至35.00美元,並對該股設定了“買入”評級。
Imago BioSciences Stock Performance
Imago BioSciences股票表現
The company's 50-day moving average is $16.20 and its 200 day moving average is $16.33. The company has a market capitalization of $507.79 million, a PE ratio of -8.46 and a beta of 2.48.
該公司的50日移動均線切入位在16.20美元,200日移動均線切入位在16.33美元。該公司市值為5.0779億美元,市盈率為-8.46,貝塔係數為2.48。
Insider Activity at Imago BioSciences
Imago BioSciences的內部活動
Hedge Funds Weigh In On Imago BioSciences
對衝基金參與Imago BioSciences
Several hedge funds and other institutional investors have recently bought and sold shares of IMGO. Ensign Peak Advisors Inc bought a new position in Imago BioSciences during the 4th quarter valued at about $593,000. Citadel Advisors LLC lifted its stake in Imago BioSciences by 20.1% during the 4th quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after acquiring an additional 410,487 shares during the period. Woodline Partners LP lifted its stake in Imago BioSciences by 101.9% during the 4th quarter. Woodline Partners LP now owns 848,129 shares of the company's stock valued at $20,109,000 after acquiring an additional 428,127 shares during the period. Emerald Advisers LLC lifted its stake in Imago BioSciences by 7.0% during the 1st quarter. Emerald Advisers LLC now owns 616,368 shares of the company's stock valued at $11,877,000 after acquiring an additional 40,209 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in Imago BioSciences by 106.6% during the 1st quarter. New York State Common Retirement Fund now owns 13,391 shares of the company's stock valued at $258,000 after acquiring an additional 6,909 shares during the period. Institutional investors own 99.50% of the company's stock.
幾家對衝基金和其他機構投資者最近買賣了IMGO的股票。Ensign Peak Advisors Inc.在第四季度購買了Imago BioSciences的一個新頭寸,價值約593,000美元。Citadel Advisors LLC在第四季度將其在Imago BioSciences的持股比例提高了20.1%。Citadel Advisors LLC在此期間額外收購了410,487股,目前擁有2,452,926股該公司股票,價值57,271,000美元。第四季度,Woodline Partners LP將其在Imago BioSciences的持股比例提高了101.9%。Woodline Partners LP在此期間額外收購了428,127股票,現在擁有848,129股該公司的股票,價值20,109,000美元。Emerald Advisers LLC在第一季度將其在Imago BioSciences的持股增加了7.0%。Emerald Advisers LLC在此期間增持了40,209股,目前擁有616,368股該公司股票,價值11,877,000美元。最後,紐約州共同退休基金在第一季度將其在Imago BioSciences的持股增加了106.6%。紐約州共同退休基金現在擁有13,391股該公司的股票,價值258,000美元,在此期間又購買了6,909股。機構投資者持有該公司99.50%的股票。
Imago BioSciences Company Profile
Imago BioSciences公司簡介
(Get Rating)
(獲取評級)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
臨牀階段生物製藥公司Imago BioSciences,Inc.發現和開發了針對賴氨酸特異性脱甲基酶1(LSD1)的小分子產品候選產品,LSD1是一種用於生產骨髓中血細胞的酶。它的主要候選產品是Bomedemstat,正在進行第二階段臨牀試驗,用於治療骨髓增生性腫瘤和慢性骨髓癌,如骨髓纖維化、原發性血小板增多症和真性紅細胞增多症。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於Imago BioSciences(IMGO)的研究報告
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 讓Paychex股票為您努力工作
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imago BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧